The Limited Times

Now you can see non-English news...

A promising new treatment for obesity


DECRYPTION - An injectable molecule opens very promising perspectives for the management of the disease.

These are data that were eagerly awaited.

Published in the

New England Journal of Medicine

on July 21, they far exceed the hopes of obesity specialists, and it is for patients, perhaps, the beginning of a new era in their care.

The phase 3 Surmont-1 clinical trial evaluated the efficacy of tirzepatide, an injectable treatment developed by the Eli Lilly laboratory.

Patients who received a weekly dose of 10 or 15 mg of tirzepatide had lost an average of 20% of their weight after 72 weeks.

This may seem limited, but the impact on their state of health is very significant.

About a third of these patients even exceed the 25% weight loss mark, this is unheard of with drugs against obesity

,” enthuses Dr. Lucie Favre, senior doctor in the endocrinology department, diabetology and metabolism at the Vaudois University Hospital Center in Lausanne (Switzerland).

Indeed, to date only surgery…

This article is for subscribers only.

You have 81% left to discover.

Pushing back the limits of science is also freedom.

Keep reading your article for €0.99 for the first month


Already subscribed?


Source: lefigaro

All tech articles on 2022-08-04

You may like

Trends 24h

Tech/Game 2022-09-20T09:57:37.018Z


© Communities 2019 - Privacy